新股消息 | 融泰药业递表港交所 为中国院外医药市场第四大营销和供应链解决方案提供商

Core Viewpoint - Guangdong Rontai Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor [1]. Company Overview - Rontai Pharmaceutical is a leading provider of out-of-hospital pharmaceutical services in China, focusing on digital marketing and supply chain solutions. It ranks as the fourth largest provider in the out-of-hospital pharmaceutical market and the largest for individual customer marketing and supply chain solutions [3]. - The company has developed a digital precision marketing system and integrates digital business and data platforms with smart logistics infrastructure, offering comprehensive pharmaceutical sales solutions to pharmaceutical companies [3]. Business Model - Rontai Pharmaceutical plays a crucial role in the e-commerce sales channels for pharmaceutical companies, sourcing products from upstream manufacturers and selling them through platforms like JD Health, Alibaba Health, Meituan Medicine, and Dingdang [3]. - The company has established its own retail pharmacy brand, Yikangsi, to directly sell pharmaceutical products to individual customers, simplifying the purchasing process and meeting the growing demand for convenience [4]. Sales Channels - In addition to e-commerce, Rontai Pharmaceutical collaborates with major national and regional chain pharmacies to enhance its sales channels, creating a comprehensive out-of-hospital retail network [6]. - The company has expanded its reach to more grassroots terminals through third-party platforms, further strengthening its penetration in the out-of-hospital market [5]. Financial Performance - For the six months ending June 30, 2022, 2023, 2024, and 2025, the company reported revenues of approximately RMB 2.427 billion, RMB 2.916 billion, RMB 2.875 billion, and RMB 1.540 billion, respectively. The net profits for the same periods were RMB 14.78 million, RMB 45.72 million, RMB 3.74 million, and RMB 17.09 million [6][7].